In the USA, the first pills for postpartum depression were approved
[ad_1]
The Food and Drug Administration (FDA) has approved a pill to help mothers overcome postpartum depression. This is reported by The Wall Street Journal. The medicine, which mothers should take every day for 2 weeks, should go on sale by the end of the year. Their manufacturers are Sage Therapeutics and its partner Biogen. The pills will be released under the trademark Zurzuvae. You need to take them once a day. This will help relieve symptoms within days instead of weeks or months with older antidepressants. Photo: Sara Monika/Gettyimages.com At the same time, doctors note that this will be the most convenient option for mothers. “This will be a vital tool for rapidly improving patient functioning,” said Dr. Christina Deligiannidis, director of women’s behavioral health at Zucker Hillside Hospital in New York. Currently, the drug must be tested by the Drug Enforcement Administration (DEA). Analysts suggest that it is classified as a controlled substance with a relatively low potential for abuse. According to the Centers for Disease Control and Prevention (CDC), postpartum depression affects one in eight mothers after giving birth in the United States, but some researchers say the true number may be higher. According to the CDC, this leads to drug overdoses and suicides. This is what causes almost one in four deaths after pregnancy. But a new drug will change that. It will stimulate a receptor in the brain that slows down and helps control anxiety and stress. The pills are said to work on women with postpartum depression who experience insomnia. Confirmation of the effect of the drug was found in experiments on women with symptoms of moderate and severe depression. They sometimes stopped showering and brushing their teeth. Also did not find the strength to change diapers and left their children crying for a long time. Zurzuvae reduced postpartum depression symptoms by nearly 55% after two weeks of treatment, compared to a 40% reduction in patients who received a placebo. The most common side effects were somnolence, dizziness, and sedation. This is not the first drug that aims to help mothers after childbirth. In 2019, it was similar, but it had to be administered intravenously. Also, women usually turned to antidepressants. BMO Capital Markets estimates that nearly 24,000 American women could be treated with Zurzuvae in 2030, generating $567 million in sales. We will remind, earlier in the USA the drug “Lakembi” was finally approved for the treatment of Alzheimer’s disease. Read also: Council allowed pregnant women to go on vacation later than 70 days before childbirth
[ad_2]
Original Source Link
